Sep 2026· Pharmacology and Therapeutics· Vol 288, pp.
109125
· 0 citations· 234 references
Medicine
Abstract
Galectin-3, a β-galactoside-binding lectin, is a driver and regulator of inflammation and fibrosis, and its levels are elevated in some heart and lung diseases. It also serves as a biomarker for the risk and severity of some forms of heart failure and, potentially, for various other pathological conditions. These observations make galectin-3 a promising potential therapeutic target. Both genetic and pharmacological inhibition of galectin-3 have been shown to ameliorate renal dysfunction and exert protective effects against liver fibrosis in animal models. Several galectin-3 inhibitors have been developed for therapeutic application in various pathological conditions. This review examines the progress of the development of 161 galectin-3 inhibitors, including monosaccharides, oligosaccharides, natural polysaccharides and their derivatives, carbohydrate polymers, antibody-drug conjugates, and non-carbohydrate compounds. Structure-activity relationships are emerging for these inhibitors, and the atypical binding pockets of galectin-3 have informed the development of a pharmacophore model that is expected to guide the design and discovery of potent, selective inhibitors for treatment of cancer, inflammation, and fibrosis.
Colorectal cancer is considered to be a highly immune-related disease, and the severe chronic inflammatory stress in the tumor microenvironment (TME) greatly impedes the effective prognosis and treatment of colorectal cancer. Based on a dual strategy, anti-proliferation and inhibition of inflammatory factor HMGB1, a se...
Jian-Rong Liu, Jing-Ke Zhang, Tianbo Wu et al.· Chinese Journal of Natural M...· 0 citations
Flavonoids are natural compounds that have shown promise against chronic inflammation. Despite sharing a common core scaffold, flavonoids exhibit substantial structural heterogeneity, and comparisons of biological activities across subclasses remain limited. These studies are often constrained by the cost and sensitivi...
Nora Pierce, Christopher Schulman, V. Yechoor et al.· Molecules· 0 citations
Type 2 diabetes (T2D) is a multifactorial metabolic disease in which hyperglycemia coexists with insulin resistance, β-cell dysfunction, dyslipidemia, and progressive microvascular and macrovascular complications. The structural versatility of the benzothiazole scaffold has enabled the development of a diverse array of...
Ana María Correa-Basurto, Miguel Valdés, L. C. Cabrera-Pérez et al.· International Journal of Mol...· 0 citations
This narrative review summarizes current data on the role of desialylation of low-density lipoproteins (LDL) as a key initiating mechanism of atherogenesis that precedes oxidative modification. The structural and functional significance of sialic acid in apolipoprotein B-100 is considered, and the enzymes of the sialid...
Tatyana I. Kovyanova, V. P. Karagodin, D. Borodko et al.· Biomolecules· 0 citations
B7-H4, a member of the B7 family, is broadly expressed on various cancer cells and has been implicated in negative immune regulation, particularly in suppressing anti-tumor immunity. However, its receptor and the mechanisms underlying its immunosuppression remain poorly understood. Here, we identify Galectin-9 (Gal-9)...
